Breaking: Promising Sonelokimab's HS Trial Data Propels MoonLake Immunotherapeutics
- June 26th, 2023
- 295 views
MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company, announced positive results from its Phase 2 MIRA trial, evaluating the effectiveness and safety of the Nanobody sonelokimab, administered subcutaneously, in patients with moderate-to-severe hidradenitis suppurativa (HS).
Hidradenitis suppurativa is a painful skin condition characterized by lumps that form in areas where skin touches skin.
The trial successfully met its primary endpoint, with a higher proportion of patients treated with sonelokimab achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 compared to those on placebo at week 12.
The results showed that sonelokimab exhibits strong clinical activity compared to other therapies evaluated in similar trials.
At present, $MLTX is trading at $47.59, representing a significant increase of $21.71 (+83.89%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
December 05th, 2025
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025
Member Login